AmyPore develops computational algorithms and a proprietary adaptive peptide platform to design innovative treatments targeting pathological conditions associated with intrinsically disordered proteins (IDPs) and membrane gangliosides.
Our lead program, AmyP53, is a first-in-class adaptive peptide for the treatment of Alzheimer's and Parkinson's diseases.
AmyPore's pioneering concept of adaptive peptides opens new therapeutic avenues for diseases that currently lack effective treatments, by directly targeting the molecular mechanisms underlying these conditions.
Our main product, AmyP53, is a therapeutic peptide derived from scientific research.
Its design is based on an innovative strategy based on molecular modeling applied to neuroscience. This strategy has made it possible to combine, in a multi-parameter specification: targeting of a fundamental mechanism common to Alzheimer's and Parkinson's diseases, low-dose therapeutic action, absence of side effects at this stage of the research, administration not invasive (nasal spray).
AmyP53 is the first representative of a new therapeutic class capable of treating Alzheimer’s and Parkinson’s diseases.
Understanding the mechanisms responsible for Alzheimer’s and Parkinson’s diseases to lead us to innovative treatments. Develop a new therapeutic class.
Our concept:
AmyP53 is active on neurons and astrocytes
AmyP53 is active on neurons and astrocytes
AmyPore is a Biotech founded in 2018 on the basis of the scientific discoveries of Pr. Nouara Yahi and Jacques Fantini, researchers in molecular neuroscience at the University of Aix-Marseille.
AmyPore is supported by the European Commission, Kedge Business School and the inter-university incubator IMPULSE.
The company obtained a grant H2020 SME Phase 1.
